NCT04270175 2026-02-27
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT04895917 2025-02-20
DarPAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Terminated
NCT06342466 2024-12-30
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Phase 2 Recruiting
NCT06455748 2024-06-12
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
First Affiliated Hospital of Wenzhou Medical University
Phase NA Recruiting
NCT06376214 2024-04-19
Daratumumab for Patients With Light Chain Amyloidosis
Nanjing University School of Medicine
Phase NA Recruiting
NCT05066607 2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2 Unknown
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01570387 2020-09-22
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT01510613 2018-03-12
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Completed